Accurate prediction and validation of response to endocrine therapy in breast cancer

ABSTRACT: Purpose Aromatase inhibitors (AIs) have an established role in breast cancer treatment. Response rates are only 50-70% in the neoadjuvant setting and lower in advanced disease. Accurate biomarkers are urgently needed to predict response in these settings and to determine which individuals will benefit from adjuvant AI therapy. Participants and Methods Pre- and on-treatment (after 2 weeks and 3 months) biopsies were obtained from 89 post-menopausal women with ER+ breast cancer receiving neoadjuvant letrozole for transcript profiling. Dynamic clinical response was assessed by three-dimensional ultrasound measurements. Results The molecular response to letrozole was characterised and a four gene classifier of clinical response was established (accuracy of 96%) based upon the level of two gen

ORGANISM(S): Homo sapiens

SUBMITTER: Andrew Sims 

PROVIDER: E-GEOD-59515 | biostudies-arrayexpress |

REPOSITORIES: biostudies-arrayexpress